Trim GILD 15-20% to 80-85% core; $138 hard stop, $143 second-trim trigger
The 15-20% trim is the calibration that converts a potentially -2% directional error into a ~flat alpha outcome, preserving optionality without realizing the floor that the franchise defends. The trader's 25-30% sits in the destruction band; the conservative analyst's 40% overshoots into overcooked defense. Patient aggression wins — trim now, reload only on confirmed momentum repair, and let the Q3 print resolve the acquisition overhang.
| Position | Action |
|---|---|
| Current levels ($145.65) | Trim 15-20% via staged limit orders at $145-147; preserve 80-85% core |
| Daily close below $143 | Execute second trim of 10-15% toward $140; aggregate exposure ~65-70% of original |
| Daily close below $138 | Hard exit remainder of position; confirms structural breakdown |
Gilead is a fundamentally undervalued biopharma compounder executing at peak operational cadence with multiple near-term catalysts, trading at a discount to peers despite $10B in annual FCF and a robust pipeline that directly addresses the long-term patent concern.
| Indicator | Value | Signal |
|---|---|---|
| close_10_ema | 147.52 | bearish |
| close_50_sma | 137.37 | bullish |
| close_200_sma | 133.58 | bullish |
| macd | 3.52 | bearish |
| macd_signal | 3.93 | bearish |
| macd_histogram | -0.42 | bearish |
| rsi | 54.69 | neutral |
| rsi_peak | 74.06 (2026-08-19) | neutral |
| boll_ub | 154.54 | neutral |
| boll_lb | 136.50 | neutral |
| boll_middle | 145.52 |
This report is AI-generated for informational and educational purposes only and is not investment advice or a recommendation to buy or sell any security. Full disclaimer.
When: Post-Q3 print with no further impairments AND deleveraging progress AND revenue beat vs. $7.9B consensus
Then: Upgrade path to Hold
Revenue growth is accelerating, not decelerating, at 8-10% YoY
↩ rebuts: “Bear claim that HIV is saturated and growth is collapsing”
EV: $152 → $154.50 · concedes: Patent cliff for Biktarvy exists and is a real concern — estimated early 2030s, approximately a decade away; MACD histogram turned negative, RSI cooled from 74 to 55, 10 EMA was given up — some technical damage occurred; Net debt increased by $8.5B due to strategic acquisition; Higher-for-longer interest rate regime can compress biotech multiples (though GILD's 0.35 beta makes it less sensitive)
GILD's "discount" is a mirage—the patent cliff will trigger multiple compression, the Q2 balance sheet shows real capital destruction from an undisclosed acquisition, and the technical picture has already broken down, making the asymmetric trade a short to $140-$138.
EV: -$140 to -$138 (downside targets from $143 entry) · concedes: Regulatory activity is not revenue; Diversification narrative is real but under-scaled relative to the franchise it's supposed to replace; The bear's risk-reward is tighter (1.2:1 to 1.4:1) rather than dramatically superior to the bull's 1:1
→ vs conservative: 0.35 beta provides no protection against a hot CPI print causing duration-sensitive complex re-rating; defensive beta gets hit equally in true risk-off; holding 100% into a binary macro event is not conservative, it is lazy risk management with no defined exit rules
→ vs conservative: $4 billion new debt issuance and $8.5 billion net debt jump in a single quarter represents a balance sheet transformation, not a footnote; $11.2 billion acquisition target not disclosed in detail means the market cannot price this asset; normalized earnings framing ignores that integration risk and competitive pressure on undisclosed acquired asset could compress multiples and question the dividend
→ vs conservative: Dividend safety narrative ignores that Biktarvy's $12 billion revenue concentration faces long-acting injectable competition and IRA patent negotiation risk; concentration risk reprices in quarters not years
→ vs neutral: Bullish sentiment score of 6.8 out of 10 is institutional-only sentiment; zero Reddit posts across wallstreetbets, stocks, and investing for seven days shows no retail confirmation; when everyone reads the same bullish news flow, you are exit liquidity not early
→ vs neutral: "Hold with constructive bias" has no defined entry or exit rules; every price level in the trader's plan is defined: add above 147.52, trim toward 140 below 143, exit below 138; hope is not a strategy
| atr | 3.68 | neutral |
| close | 145.65 | neutral |
Support: 136.5 · 138 · 140 · 143 | Resistance: 147.52 · 152 · 154.54
GILD is in a healthy medium-term uptrend (50 SMA rising from $129.45 in late July to $137.37 today; price 9% above 200 SMA) that is currently consolidating just below short-term resistance at the 10 EMA ($147.52) and sitting on the Bollinger middle band ($145.52); the pullback off $152.55 (9/02) is normal, but the loss of the 10 EMA and the bearish MACD histogram cross (-0.42) warrant watching closely. A hold above $143-$145 keeps the bullish setup alive; a decisive break below $138 (50 SMA + lower BB confluence) would invalidate it. ATR of $3.68 supports a $7.4 stop (2× ATR) below entry; the path of least resistance remains up unless $138 gives way.
Market Cap
$180.6B
Beta
0.35
52-Week Range
$108.46 – $157.29
50-Day MA
$136.98
200-Day MA
$134.46
Forward P/E
14.73
PEG Ratio
2.02
P/B
15.28
EPS (TTM)
-$2.65
Forward EPS
$9.89
Dividend Yield
2.24%
Free Cash Flow (TTM)
$9.77B
Revenue (TTM)
$30.46B
Gross Profit (TTM)
$24.25B
EBITDA (TTM)
$14.60B
Operating Margin
33.7%
Normalized EBITDA Margin
~45%
Q2 2026 Revenue YoY Growth
+10.2%
Q1 2026 Revenue YoY Growth
+8.6%
Gross Margin
~80%
Cash & Equivalents (Q2 2026)
$3.18B
Total Assets (Q2 2026)
$49.36B
Goodwill (Q2 2026)
$8.31B
Other Intangibles (Q2 2026)
$14.03B
Total Debt (Q2 2026)
$26.25B
Stockholders' Equity (Q2 2026)
$11.83B
Net Debt (Q2 2026)
$23.07B
Current Ratio (Q2 2026)
1.27
Annual Dividends
~$4.0B
Annual Buybacks
~$1.4B
Q2 2026 Acquisition Spend
$11.21B
Q2 2026 New Debt Issued
$4.07B
Q2 2026 Special Charges
$12.93B
Q2 2026 Net Income
-$10.496B
Q2 2026 Diluted EPS
-$8.45
Q2 2026 Operating Income (ex-special)
$2.539B
Q2 2026 Operating CF
$3.57B
Q2 2026 CapEx
$0.14B
Q2 2026 FCF
$3.43B
Q2 2026 Revenue
$7.803B
Q1 2026 Revenue
$6.960B
Q4 2025 Revenue
$7.924B
Q3 2025 Revenue
$7.769B
Q2 2025 Revenue
$7.081B
Strengths
Concerns
Gilead Sciences reported severely distorted Q2 2026 results with a net loss of -$10.496B due to $12.933B in one-time acquisition-related charges, including $11.18B in special charges and $1.75B capital asset impairment from a major $11.209B M&A transaction. However, underlying business fundamentals remain strong with ~$2.5B operating income on $7.8B revenue (~33% operating margin, ~45% normalized EBITDA margin), $9.77B TTM free cash flow, and ~10% revenue growth driven by the HIV franchise and oncology ramp. The company trades at an attractive 14.73x forward P/E with a 2.24% dividend yield, though leverage increased materially with net debt rising to $23.07B following the acquisition.
Macro: "Will no Fed rate cuts happen in 2026?" Polymarket: 93% Yes (~$8.2M volume, +4.0pp on the week). All sub-markets for ≥6 cuts price at 0%. Higher-for-longer discount-rate backdrop historically compresses duration-heavy biotech multiples. US recession by end-2026: 8%, UK 6%, Japan 6% — tails benign; not a risk-off tape. Crude firm (supportive of healthcare relative-value). Equity indices show inflation data due overhang from IBD — next CPI/PCE prints (mid-Sep) are dominant near-term catalyst for rate-sensitive complex.